A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)

This study is testing a drug called VK-2019 for people with a specific type of lymphoma — EBV-positive diffuse large B-cell lymphoma (DLBCL). This is an aggressive blood cancer linked to the Epstein-Barr virus (the same virus that causes mononucleosis). The study is for patients whose cancer came back or stopped responding to previous treatments. **You may be eligible if...** - You are 18 years or older - You have EBV-positive DLBCL that has relapsed (come back) or is refractory (not responding) after at least 2 prior treatment regimens - You have exhausted all standard treatment options that might benefit you - You have measurable disease on a scan - Your performance status is ECOG 2 or below (able to carry out some self-care) - Side effects from prior treatment have resolved to mild or stable levels - Your organ function meets required minimums **You may NOT be eligible if...** - You have not tried at least 2 prior treatment regimens - There are still standard treatment options available that could help you - Your prior treatment ended less than 2 weeks ago - You have significant unresolved side effects from prior therapy - Your organ function is not adequate Talk to your doctor to see if this trial is right for you.